Stock News

Willis Investment Counsel Decreased Its Maxim Integrated Prods (MXIM) Holding; Casi Pharmaceuticals (CASI) Sellers Decreased By 36.56% Their Shorts

Casi Pharmaceuticals Incorporated (NASDAQ:CASI) had a decrease of 36.56% in short interest. CASI’s SI was 259,900 shares in December as released by FINRA. Its down 36.56% from 409,700 shares previously. With 525,700 avg volume, 1 days are for Casi Pharmaceuticals Incorporated (NASDAQ:CASI)’s short sellers to cover CASI’s short positions. The SI to Casi Pharmaceuticals Incorporated’s float is 0.72%. The stock decreased 16.38% or $0.655 during the last trading session, reaching $3.345. About 1.31M shares traded or 43.85% up from the average. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since December 7, 2016 and is downtrending. It has underperformed by 34.35% the S&P500.

Willis Investment Counsel decreased Maxim Integrated Prods (MXIM) stake by 23.37% reported in 2017Q2 SEC filing. Willis Investment Counsel sold 96,900 shares as Maxim Integrated Prods (MXIM)’s stock rose 3.86%. The Willis Investment Counsel holds 317,700 shares with $14.27M value, down from 414,600 last quarter. Maxim Integrated Prods now has $14.50 billion valuation. The stock decreased 0.27% or $0.14 during the last trading session, reaching $51.5. About 1.33 million shares traded. Maxim Integrated Products, Inc. (NASDAQ:MXIM) has risen 31.27% since December 7, 2016 and is uptrending. It has outperformed by 14.57% the S&P500.

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. Maxim Group initiated it with “Buy” rating and $4 target in Thursday, September 22 report. H.C. Wainwright initiated CASI Pharmaceuticals, Inc. (NASDAQ:CASI) on Thursday, October 29 with “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Monday, August 14.

Investors sentiment increased to 1.67 in 2017 Q2. Its up 0.92, from 0.75 in 2017Q1. It is positive, as 0 investors sold CASI Pharmaceuticals, Inc. shares while 6 reduced holdings. 5 funds opened positions while 5 raised stakes. 2.29 million shares or 2.19% less from 2.34 million shares in 2017Q1 were reported. Geode Capital Mngmt Ltd Liability stated it has 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Raymond James Financial Services Advsr accumulated 55,135 shares or 0% of the stock. Bank & Trust Of America De holds 1,171 shares. Northern owns 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 31,034 shares. Wells Fargo And Mn holds 0% or 68 shares in its portfolio. Manatuck Hill Partners Ltd Com has 0.01% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields & Limited holds 505,474 shares or 0.18% of its portfolio. Citadel Advisors Ltd Liability Co accumulated 20,713 shares. Deutsche Financial Bank Ag holds 21 shares. Morgan Stanley holds 0% or 1,133 shares. 106,200 are held by Renaissance Tech. Vanguard Gp holds 0% or 287,890 shares in its portfolio. Wellington Shields Mngmt Ltd Com holds 0.12% or 726,069 shares. Royal Bank & Trust Of Canada owns 17,545 shares. Moreover, Next Gru has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 2 shares.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $217.65 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Investors sentiment increased to 1.18 in Q2 2017. Its up 0.07, from 1.11 in 2017Q1. It increased, as 33 investors sold MXIM shares while 142 reduced holdings. 62 funds opened positions while 144 raised stakes. 249.67 million shares or 0.74% more from 247.83 million shares in 2017Q1 were reported. Rafferty Asset Mngmt Llc invested in 0.21% or 164,347 shares. Moreover, Asset Mgmt One has 0.07% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM) for 580,744 shares. Proshare Advsrs Lc holds 101,989 shares. Of Vermont stated it has 0.34% in Maxim Integrated Products, Inc. (NASDAQ:MXIM). Cap World has invested 0.04% of its portfolio in Maxim Integrated Products, Inc. (NASDAQ:MXIM). Sg Americas Secs Ltd Limited Liability Company holds 0.19% of its portfolio in Maxim Integrated Products, Inc. (NASDAQ:MXIM) for 475,093 shares. Nikko Asset Mngmt Americas Inc invested in 36,300 shares. Payden & Rygel holds 1.74% or 442,700 shares in its portfolio. Da Davidson & Co owns 0.01% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM) for 9,452 shares. Johnson Fin Group has 0.01% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM). Boston Private Wealth Ltd accumulated 56,342 shares. Tfs Ltd Liability Corp has 0.17% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM). Moneta Inv Ltd reported 0.07% stake. Tci Wealth Advisors Incorporated, Arizona-based fund reported 186 shares. California State Teachers Retirement System accumulated 517,971 shares.

Willis Investment Counsel increased Coca Cola Company (NYSE:KO) stake by 67,600 shares to 435,200 valued at $19.52 million in 2017Q2. It also upped Patriot Transportation stake by 21,340 shares and now owns 97,191 shares. Chubb Ltd was raised too.

Among 29 analysts covering Maxim Integrated Products Inc. (NASDAQ:MXIM), 15 have Buy rating, 2 Sell and 12 Hold. Therefore 52% are positive. Maxim Integrated Products Inc. had 72 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Maxim Integrated Products, Inc. (NASDAQ:MXIM) has “Market Perform” rating given on Friday, October 20 by BMO Capital Markets. The firm has “Hold” rating by RBC Capital Markets given on Tuesday, September 5. BMO Capital Markets maintained Maxim Integrated Products, Inc. (NASDAQ:MXIM) on Monday, October 16 with “Hold” rating. The stock of Maxim Integrated Products, Inc. (NASDAQ:MXIM) earned “Buy” rating by Drexel Hamilton on Friday, January 27. The stock of Maxim Integrated Products, Inc. (NASDAQ:MXIM) has “Market Perform” rating given on Tuesday, July 19 by BMO Capital Markets. The stock has “Buy” rating by Loop Capital on Tuesday, December 6. The stock of Maxim Integrated Products, Inc. (NASDAQ:MXIM) earned “Hold” rating by BMO Capital Markets on Monday, September 4. Loop Capital maintained Maxim Integrated Products, Inc. (NASDAQ:MXIM) rating on Friday, October 20. Loop Capital has “Buy” rating and $57 target. As per Friday, October 20, the company rating was maintained by KeyBanc Capital Markets. On Monday, August 14 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *